证券记录 · 已归档季度
CTMX
CytomX Therapeutics, Inc. · Healthcare · Biotechnology
14被追踪持有人
0Δ持有人
41.38M持有股份
$131.99M报告持仓市值
+0新建仓位
−0清仓
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 +11.9% · 净新建仓位 0.0% — 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | +11 | 136.41M | $511.64M | +18 | −7 |
| Q1 2026 | 64 | +15 | 111.19M | $522.57M | +20 | −5 |
| Q4 2025 | 49 | -1 | 71.30M | $303.77M | — | −1 |
| Q3 2025 | 14 | 0 | 41.38M | $131.99M | — | — |
| Q2 2025 | 11 | 0 | 36.17M | $82.10M | — | — |
| Q1 2025 | 8 | +1 | 8.01M | $5.09M | +1 | — |
| Q4 2024 | 7 | 0 | 9.00M | $9.27M | +1 | −1 |
| Q3 2024 | 6 | 0 | 8.17M | $9.64M | — | — |
| Q2 2024 | 6 | — | 7.95M | $9.70M | — | — |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 15.40M | +66.7% | $49.11M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Fidelity (FMR) ✦ | 15.40M | +66.7% | $49.11M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Fidelity (FMR) ✦ | 15.40M | +66.7% | $49.11M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | The Vanguard Group ✦ (被动) | 8.95M | -4.6% | $28.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | The Vanguard Group ✦ (被动) | 8.95M | -4.6% | $28.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | The Vanguard Group ✦ (被动) | 8.95M | -4.6% | $28.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Point72 Asset Management ✦ | 4.07M | -49.7% | $12.98M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 2.55M | +36.7% | $8.12M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 9 | BlackRock ✦ (被动) | 2.38M | -0.3% | $7.60M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | BlackRock ✦ (被动) | 2.38M | -0.3% | $7.60M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | BlackRock ✦ (被动) | 2.38M | -0.3% | $7.60M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | BlackRock ✦ (被动) | 2.38M | -0.3% | $7.60M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 1.80M | +2005.5% | $5.74M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 1.80M | +2005.5% | $5.74M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 15 | Geode Capital Management ✦ (被动) | 1.57M | -10.1% | $5.01M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | Geode Capital Management ✦ (被动) | 1.57M | -10.1% | $5.01M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | Millennium Management ✦ | 1.39M | +494.4% | $4.42M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 18 | Marshall Wace ✦ | 1.10M | -53.0% | $3.52M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | Marshall Wace ✦ | 1.10M | -53.0% | $3.52M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 729.70K | +362.8% | $2.33M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | State Street Global Advisors ✦ (被动) | 644.98K | +0.9% | $2.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 22 | Goldman Sachs Group ✦ | 447.75K | — | $1.43M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Goldman Sachs Group ✦ | 447.75K | — | $1.43M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Morgan Stanley ✦ | 319.29K | — | $1.02M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Morgan Stanley ✦ | 319.29K | — | $1.02M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | Morgan Stanley ✦ | 319.29K | — | $1.02M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Morgan Stanley ✦ | 319.29K | — | $1.02M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | JPMorgan Chase ✦ | 32.30K | — | $103,050 | 0.0% | n/c | 1 | SEC ↗ |
| 29 | JPMorgan Chase ✦ | 32.30K | — | $103,050 | 0.0% | n/c | 1 | SEC ↗ |
| 30 | JPMorgan Chase ✦ | 32.30K | — | $103,050 | 0.0% | n/c | 1 | SEC ↗ |
| 31 | JPMorgan Chase ✦ | 32.30K | — | $103,050 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 178 持有人, 193.14M 股份, $906.86M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据